Conference Coverage ACC 2017 See All Content See past conferences Washington, DC March 17, 2017 March 19, 2017 Editor's Corner My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time My prediction? The biggest impact of ACC 2017 won’t come from a trial, a drug, or a device, but from the faces we saw in the Main Tent. < > FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017 SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients Todd Neale March 17, 2017 News News • Interventional DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions Yael L. Maxwell March 19, 2017 News • Interventional iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017 News • Interventional FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017 News • Interventional MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns L.A. McKeown March 27, 2017 News • Interventional TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes Shelley Wood March 24, 2017 Slides Presentation First Results from the SURTAVI Clinical Trial Presenter: Michael J. Reardon March 17, 2017 Presentation DECISION-CTO: Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Presenter: Seung-Jung Park March 20, 2017 Presentation iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART Presenter: Matthias Götberg March 20, 2017 Presentation The RAD-MATRIX Study Presenter: Alessandro Sciahbasi March 19, 2017 Presentation Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis Presenter: Stephen J Nicholls March 20, 2017 Live Blog Editor's Corner Live From Washington: ACC 2017, Day One Shelley Wood March 17, 2017 Editor's Corner Live From Washington: ACC 2017, Day Two Shelley Wood March 18, 2017 Editor's Corner Live From Washington: ACC 2017, Day Three Shelley Wood March 19, 2017
Editor's Corner My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time My prediction? The biggest impact of ACC 2017 won’t come from a trial, a drug, or a device, but from the faces we saw in the Main Tent.
FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News • Interventional DECISION-CTO: PCI Stumbles for Stable CAD Patients With Chronic Total Occlusions Yael L. Maxwell March 19, 2017
News • Interventional iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017
News • Interventional FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS Michael O'Riordan March 18, 2017
News • Interventional MitraClip Commercial Experience at 1 Year Sheds Light on Progress and Lingering Concerns L.A. McKeown March 27, 2017
News • Interventional TAVR for Bicuspid Aortic Stenosis? Registry Offers Clues to Safety, Outcomes Shelley Wood March 24, 2017
Presentation First Results from the SURTAVI Clinical Trial Presenter: Michael J. Reardon March 17, 2017
Presentation DECISION-CTO: Optimal Medical Therapy With or Without Stenting For Coronary Chronic Total Occlusion Presenter: Seung-Jung Park March 20, 2017
Presentation iFR vs FFR-guided Coronary Intervention – iFR-SWEDEHEART Presenter: Matthias Götberg March 20, 2017
Presentation Results of the CARAT Study: Effect of Serial Infusions of CER-001, a Pre-Beta High-Density Lipoprotein Mimetic on Coronary Atherosclerosis Presenter: Stephen J Nicholls March 20, 2017